4.7 Review

Biochemical pathways of copper complexes: progress over the past 5 years

Journal

DRUG DISCOVERY TODAY
Volume 26, Issue 4, Pages 1086-1096

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.01.015

Keywords

-

Funding

  1. University Grants Commission (UGC), CSIR-HRDG, New Delhi [09/112(0660) 2020-EMR-I]
  2. Department of Chemistry, AMU through the UGC-assisted DRS-SAP Programme
  3. Department of Chemistry, AMU through the DST-FIST Programme
  4. Department of Chemistry, AMU through the DST PURSE Programme

Ask authors/readers for more resources

Copper is a vital trace element with important roles in metalloenzymes and is a key component in nonplatinum anticancer metallodrugs. Copper-based complexes have shown to be more potent than cisplatin with fewer side effects, making them promising candidates for improving cancer treatment outcomes.
Copper is an essential trace element with vital roles in many metalloenzymes; it is also prominent among nonplatinum anticancer metallodrugs. Copper-based complexes are endogenously biocompatible, tenfold more potent than cisplatin, exhibit fewer adverse effects, and have a wide therapeutic window. In cancer biology, copper acts as an antitumor agent by inhibiting cancer via multiple pathways. Herein, we present an overview of advances in copper complexes as 'lead' antitumor drug candidates, and in understanding their biochemical and pharmacological pathways over the past 5 years. This review will help to develop more efficacious therapeutics to improve clinical outcomes for cancer treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
Review Pharmacology & Pharmacy

Illuminating the druggable genome: Pathways to progress

Karlie R. Sharma, Christine M. Colvis, Griffih P. Rodgers, Douglas M. Sheeley

Summary: There are many genes within the druggable genome that have not been studied, and the US National Institutes of Health's program provides resources to explore these genes, with the potential for rapid impact on human health.

DRUG DISCOVERY TODAY (2024)

Review Pharmacology & Pharmacy

Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment

Mohammad Sameer Khan, B. H. Jaswanth Gowda, Waleed H. Almalki, Tanuja Singh, Amirhossein Sahebkar, Prashant Kesharwani

Summary: Mitochondria-specific functional liposomes hold great potential for cancer therapy. This review discusses the association between mitochondria and tumor formation, as well as the advantages of liposomes in delivering drugs to mitochondria.

DRUG DISCOVERY TODAY (2024)

Review Pharmacology & Pharmacy

Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities

Choong Yong Ung, Cristina Correia, Hu Li, Christopher M. Adams, Jennifer J. Westendorf, Shizhen Zhu

Summary: With increasing human life expectancy, the global medical burden of chronic diseases is growing. Chronic diseases often involve malfunctioning of multiple organs, and understanding the interorgan crosstalk is crucial to understanding the etiology of chronic diseases. Researchers have proposed the locked-state model (LoSM) and cutting-edge systems biology and artificial intelligence strategies to decipher chronic multiorgan locked states. The findings have important clinical implications for improving treatments for chronic diseases.

DRUG DISCOVERY TODAY (2024)